AGP
MLYS icon

Artia Global Partners’s Mineralys Therapeutics MLYS Stock Holding History

Artia Global Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.72M Hold
137,800
– – 0.69% 34
2026
Q1 		$3.73M Hold
137,800
– – 0.75% 26
2025
Q4 		$5M Buy
137,800
+81,200
+143% +$3.26M 0.71% 23
2025
Q3 		$2.15M Buy
56,600
+15,500
+38% +$335K 0.34% 31
2025
Q2 		$556K Buy
+41,100
New +$596K 0.13% 34

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Artia Global Partners's MLYS Position: Q2 2026 in Review

Artia Global Partners held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 137,800 shares worth $3.72M. The position accounts for 0.69% of the portfolio, ranked #34.

Artia Global Partners first reported a position in MLYS in Q2 2025 and has held it in 5 quarters since. The position peaked at $5M in Q4 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Artia Global Partners held 137,800 shares of Mineralys Therapeutics worth $3.72M as of Q2 2026.
  • Artia Global Partners left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up 0.69% of Artia Global Partners's portfolio in Q2 2026, its #34 holding.
  • Artia Global Partners first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Artia Global Partners's Mineralys Therapeutics position peaked at $5M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.